Innovative New Products and Technology Advancing Worldwide Liver Disease Management Highlight Echosens 20th Anniversary
14.12.2021 17:54:00 EET | Business Wire | Press release
Echosens, a high-technology company offering the FibroScan® portfolio of solutions, is pleased to celebrate its 20th consecutive year pioneering the field of liver diagnosis and management. Recognized worldwide as the reference for liver fibrosis and liver steatosis assessment, with more than 3,000+ peer-reviewed publications and 140+ international guidelines, Echosens continues to show an unparalleled commitment to innovation. In the past year alone Echosens launched three new global products all carefully designed to optimize the overall FibroScan experience.
A year ago, Echosens launched their flagship and most advanced product, the FibroScan Expert 630. This device is the complete non-invasive solution for liver disease management, powered by liver stiffness measurement (LSM by VCTE) CAP and spleen stiffness measurement (SSM by VCTE) as part of an overall assessment of the liver.
Echosens then launched SmartExam software, which unlocks three key benefits for users: improved reliability in the diagnosis and monitoring of steatosis with continuous CAP; extended usage among severely obese patients with deeper assessment of liver fibrosis and steatosis; and task automation features that enable physicians to dedicate more time to patient care.
Recently, Echosens launched FibroScan-based Agile scores to easily detect advanced fibrosis and cirrhosis in non-alcoholic fatty liver disease (NAFLD) patients. Included on the free myFibroScan app, users can now assess a patient's liver health in just a few clicks, making interpreting results quicker and easier than ever.
“Our long-term commitment to innovation optimizes the FibroScan portfolio of solutions, representing a major step toward winning the worldwide battle against liver disease,” says Dominique Legros, Group CEO, Echosens. “We’re highly grateful to our team leaders and champions for continuing to challenge the status quo in improving the management of silent, underdiagnosed chronic liver disease, which includes NAFLD and its more severe form nonalcoholic steatohepatitis (NASH). A number of chronic liver diseases can be reversible if diagnosed early.”
He points to the FibroScan Expert 630 as an innovative tool designed to expand clinical capabilities in liver health assessment with the addition of SSM by VCTE. This tool potentially supplies a cost-effective, non-invasive modality for spleen and liver stiffness measurements that may be used as an aid in the diagnosis, monitoring and clinical management of adult patients with liver disease.
For more than two decades, Echosens has generated robust clinical data that is extremely valuable in helping providers, benefits decision-makers and payers understand how a point-of-care examination can improve the quality of specialist referrals – reducing waste from unnecessary and often invasive testing. This was validated in an independent assessment conducted by Santa Barbara Actuaries Inc. (SBA) and published in the September 2021 issue of the American Journal of Managed Care.
“Furthermore, the National Institute for Health and Care Excellence (NICE), the United Kingdom’s health technology assessment body providing national guidance and advice to improve health and social care, issued a MedTech Innovation Briefing (MIB) dedicated to utilization of FibroScan non-invasive technology in the primary care setting,” says Legros. “Additionally, new guidelines from the European Association for the Study of the Liver (EASL), a professional association for those researching liver disease, outlined an unprecedented level of recommendation for Echosens’ solutions.”
Jon Gingrich, CEO, Echosens North America, states, “During our anniversary year, it is gratifying to highlight the exciting technological advances we have developed and introduced to the healthcare industry. We have demonstrated our commitment to innovation and value in the field, reflected by the essential and actionable data to support and advance liver health management.”
Listen to episodes of eHealth Radio Network, featuring some of today’s leading innovators in healthcare and wellness.
About Echosens
Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan®, the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by over 3,000 peer reviewed publications and 140 international guidelines. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005010/en/
Contact information
Media:
Brittany Tedesco
CPR Communications
btedesco@cpronline.com
201.641.1911 x 14
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Appoints Herb Yeh as Chief Financial Officer and Chief Strategy Officer20.7.2026 14:01:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain planning and orchestration, today announced the appointment of Herb Yeh as Chief Financial Officer and Chief Strategy Officer, effective July 27, 2026. In this role, Yeh will oversee the global finance organization and corporate strategy operations at Kinaxis, leading all Finance, Accounting, Investor Relations, Corporate Strategy, and Corporate Development. He will work closely with the executive leadership team and Board of Directors to support disciplined execution, long-term growth, and shareholder value creation. "Herb has spent his career working with boards and management teams at their most critical inflection points in enterprise software, and we are thrilled to have him join Kinaxis," said Razat Gaurav, Chief Executive Officer of Kinaxis. "He has followed Kinaxis and the broader supply chain technology sector closely for more than a decade, and that depth of perspective, paired with his expertise advising companies on c
IFF Announces Agreement to Sell Its Portfolio of Botanical Extracts, Vitamins & Minerals and Food Enhancement Activities to SuanNutra, a Portfolio Company of Carbyne Equity Partners.20.7.2026 13:45:00 EEST | Press release
IFF (NYSE: IFF) — a global leader in flavors, fragrances, and health and biosciences — today announced that it has entered into an agreement with SuanNutra, a Carbyne Equity Partners portfolio company and global provider of science-backed branded and functional ingredients, to sell its portfolio of botanical extracts, vitamins and minerals, and food enhancement activities, including its range of natural colors and antioxidants and certain localized flavor activities in Peru. The portfolio serves a broad range of food, beverage and nutritional end markets through a comprehensive selection of customized solutions. “These businesses are highly respected, and we are confident they will continue to thrive under the ownership of SuanNutra and Carbyne,” said Erik Fyrwald, CEO IFF. “This transaction is another step in optimizing our portfolio and reinforces our focus on our core innovation-led businesses — Taste, Scent and Health & Biosciences — where we see the greatest opportunities to drive
NIQ Appoints Irina Stoian as Chief AI Commercial Officer20.7.2026 13:45:00 EEST | Press release
NIQ today announced that Irina Stoian has joined the company as Chief AI Commercial Officer, a newly created role designed to accelerate NIQ’s enterprise AI commercial strategy and help clients turn the company’s AI capabilities into business impact and growth. Stoian will help align Product, Technology, Commercial, Partnerships, and Marketing around a unified AI growth strategy. Her remit includes shaping commercial AI offerings, strategic partnerships, pricing and business models, and deeper integration of NIQ capabilities into client workflows. The appointment builds on NIQ’s broader AI strategy, which positions the company as a trusted intelligence infrastructure powering AI-driven commerce. Across its AI portfolio, including ConnectAI, NIQ Optiq™, and NIQ Cadence™, NIQ is expanding how clients access trusted data, intelligence, and AI-powered workflows. “AI is not a feature we are adding to NIQ; it is core to our product strategy,” said Jim Peck, Chief Executive Officer of NIQ. “I
Wolters Kluwer Named Top Vendor Law Firm SaaS Solution Provider in the DACH Region for 202720.7.2026 10:00:00 EEST | Press release
Wolters Kluwer’s Legal & Regulatory has been recognized as a top vendor for Law Firm SaaS Solutions in the DACH region for 2027, according to the latest Vendor Selection Matrix™ by Research in Action. Kleos, the company's cloud-native legal practice management platform, achieved a shared first-place position in the ranking and received the highest scores for customer satisfaction, value for money and customer recommendation among surveyed law firms in Germany, Austria and Switzerland. The recognition builds on the platform's earlier pan-European leadership position and reinforces Kleos' standing as one of Europe's leading legal practice management solutions. "We are proud to be recognized as a leading provider of Law Firm SaaS Solutions in the DACH region,” said Sergio Liscia, Vice President Legal Software at Wolters Kluwer. “What makes this recognition particularly meaningful is that it reflects the experience of legal professionals themselves. Achieving the highest ratings for custom
IQM and Deutsche Bahn Demonstrate Quantum Algorithm for Railway Scheduling on Real Operational Data20.7.2026 09:00:00 EEST | Press release
IQM Quantum Computers (Nasdaq: IQMX), a global leader in full-stack superconducting quantum computers, today published the results of a research collaboration with Deutsche Bahn, Europe’s largest rail operator, exploring how quantum computing can improve railway scheduling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260719172592/en/ IQM's whitepaper on hybrid quantum optimization for railway scheduling, developed with Deutsche Bahn. Using a real operational dataset from Deutsche Bahn, a schedule of 190 trips across five German cities translating into roughly 98,500 possible cycles, the two organizations developed and tested a hybrid quantum-classical algorithm designed for enterprise-scale optimization problems. As detailed in a published whitepaper here, the IQM team applied the Quantum Approximate Optimization Algorithm (QAOA) in manageable stages, with the quantum component solving smaller subproblems within a classic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom